How Prostate Cancers Become Resistant to Androgen Deprivation Therapies Seen in Study

How Prostate Cancers Become Resistant to Androgen Deprivation Therapies Seen in Study
Understanding how prostate cancer cells develop resistance to androgen deprivation therapies is critical to developing therapies that restore sensitivity to such agents, improving the treatment — and the chances — of people with castration-resistant prostate cancer. Researchers recently identified two tumor-suppressor proteins, TP53 and RB1, that are lost in the transition from androgen-dependent to androgen-independent cells. They also found

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , .

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

Leave a Comment

Your email address will not be published. Required fields are marked *